About NPS Pharma
NPS Pharma is a Healthcare company based in Bedminster (United States) founded in 1986, and was acquired by Shire in January 2015. Biopharmaceutical treatments for rare gastrointestinal and endocrine disorders are developed. NPS Pharma has raised $50 million across 1 funding round from investors including Takeda Pharmaceuticals. NPS Pharma offers products and services including Medicines for Gastrointestinal, Oncology Drugs, Plasma-Derived Therapies, and Vaccine Developments. Its focus areas include Diversified Pharmaceuticals, Drugs, Biopharma Outsourcing and Diversified. Its legal entity is Takeda Pharmaceutical Company Limited. Its competitors include Roivant Sciences, AbbVie and Gilead; 1 of its 3 listed competitors has raised funding.
Company details
Founded in 1986, NPS Pharma operated as a biopharmaceutical company specializing in rare diseases, particularly gastrointestinal and endocrine disorders. Its lead product, GattexRevestive (teduglutide), was approved in the United States and Europe for adults with short bowel syndrome dependent on parenteral support. A registration-stage product, NatparaNatpar (rhPTH 1-84), targeted hypoparathyroidism. The company, based in Bedminster, United States, was acquired by Shire in February 2015 for approximately 5.2 billion USD.
- Total Equity Funding$50M (USD)
in 1 rounds
- Latest Funding Round$50M (USD), Private Equity Round
Aug 2014
- Investors
- Acquired byShire
(Jan 2015)
Products & Services of NPS Pharma
NPS Pharma offers a comprehensive portfolio of products and services, including Medicines for Gastrointestinal, Oncology Drugs, Plasma-Derived Therapies, and Vaccine Developments.
Treatments for gastrointestinal and inflammatory conditions
Innovative therapies for cancer patients
Products for chronic and complex diseases
Vaccines addressing global health needs
Funding Insights of NPS Pharma
NPS Pharma has successfully raised a total of $50M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $50 million completed in August 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50M
- Total Rounds 1
- Last Round Private Equity Round — $50M
- First Round $50M
(Aug 2014)
All 1 funding rounds of NPS Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2014 | $50M | Private Equity Round | – | – | – |
1 investors in total: 1 institutional.
Investors in NPS Pharma
NPS Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Rare disease treatments are developed by a specialty biopharmaceutical firm. | 1986 | shire.com | Dublin, Ireland |
Investor details for NPS Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NPS Pharma
3 dated milestones of NPS Pharma across 29 years, from founding to its latest funding, stage changes and deals.
- Founded NPS Pharma is founded.
- Funding First funding round of $50.0M.
- Exit Acquired by Shire.
Competitors of NPS Pharma
NPS Pharma has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, AbbVie and Gilead.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | ||
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others |
Detailed competitors of NPS Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NPS Pharma
Websites that share an audience with NPS Pharma (npsp.com).
Websites whose visitors overlap most with NPS Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ligand.com | 100% | 7K | #3,254,882 | View details | |
us.sandoz.com | us.sandoz.com | 87% | – | ||
aplagen.com | aplagen.com | 87% | – | ||
| biotech-concepts.com | 87% | View details | |||
samaritanpharma.com | samaritanpharma.com | 87% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 28 similar websites and full traffic analytics for NPS Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 28 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as NPS Pharma (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nps Pharma
Complete news archive for NPS Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NPS Pharma
NPS Pharma was founded in 1986 and raised its 1st funding round 28 years after it was founded.
NPS Pharma is headquartered in Bedminster, United States. It is registered at Bedminster, New Jersey, United States.
NPS Pharma is a funded company, having raised a total of $50M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $50M, raised on Aug 2014.
Founded in 1986, NPS Pharma operated as a biopharmaceutical company specializing in rare diseases, particularly gastrointestinal and endocrine disorders. Its lead product, GattexRevestive (teduglutide), was approved in the United States and Europe for adults with short bowel syndrome dependent on parenteral support. A registration-stage product, NatparaNatpar (rhPTH 1-84), targeted hypoparathyroidism. The company, based in Bedminster, United States, was acquired by Shire in February 2015 for approximately 5.2 billion USD.
NPS Pharma's top competitors include Roivant Sciences, AbbVie and Gilead.
NPS Pharma offers Medicines for Gastrointestinal, Oncology Drugs, Plasma-Derived Therapies, and Vaccine Developments.
NPS Pharma has 1 investor. Key investors include Takeda Pharmaceuticals.
NPS Pharma operates through Takeda Pharmaceutical Company Limited.
Yes. NPS Pharma was acquired by Shire in January 2015.